Vasopressin Receptor
信号通路图
研究领域
- 抑制剂选择性比较
- 溶解性比较
| 目录号 | 产品目录 | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | 酒精 | ||
| S2116 | Conivaptan HCl | <1 mg/mL | 107 mg/mL | 7 mg/mL |
| S2593 | Tolvaptan | <1 mg/mL | 89 mg/mL | 6 mg/mL |
| S2920 | Mozavaptan | <1 mg/mL | 1 mg/mL | 1 mg/mL |
- Vasopressin Receptor抑制剂（3）
| 产品目录 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S2116 |
Conivaptan HClConivaptan HCl 是一种非肽类抗利尿激素抑制剂（加压素受体拮抗剂）。 |
Select hit drugs from each class identified from the Selleck screen were assayed at 0.25X, 0.5X, and 1X MIC for their ability to prevent biofilm formation in vitro. Data were normalized to DMSO control. * p<0.05 (Student’s t-Test; two-tailed).
|
|
| S2593 |
TolvaptanTolvaptan是一种选择性，竞争性的精氨酸加压素受体2拮抗剂，抑制AVP-诱导的血小板聚集，IC50为1.28µM。 |
Immunoblots of inner medullas from control and tolvaptan-treated rats. Each lane was loaded with a sample from a different rat. Tolvaptan (2.5 mg/day) or vehicle was infused for 4 days. Loading: aquaporin-2 (AQP2), 15 μg; AQP3, 20 μg; AQP4, 25 μg; and urea transporter UT-A1, 25 μg. Values are normalized band densities covering all bands (means ± SE). *Statistical significance (P < 0.05, t-test).
|
|
| S2920 |
MozavaptanMozavaptan是一种新型，竞争性的vasopressin受体拮抗剂，作用于V1和V2受体，IC50分别为1.2 μM和14 nM。 |
